- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-05-26
DOI
10.1007/s40262-018-0679-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range
- (2017) Michael J. Hanley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
- (2017) Jinghua Liu et al. Oncotarget
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management
- (2015) Julie M. Vose AMERICAN JOURNAL OF HEMATOLOGY
- Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
- (2015) Ruben Niesvizky et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort
- (2015) Angela Grelaud et al. LEUKEMIA & LYMPHOMA
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib for the treatment of non-Hodgkin’s lymphoma
- (2014) Prithviraj Bose et al. EXPERT OPINION ON PHARMACOTHERAPY
- Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
- (2013) Zhiyong Zeng et al. ANNALS OF HEMATOLOGY
- Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
- (2013) M. A. Dimopoulos et al. BLOOD
- Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
- (2013) R W F van Leeuwen et al. BRITISH JOURNAL OF CANCER
- Bortezomib-containing induction regimens in transplant-eligible myeloma patients
- (2013) Ajay K. Nooka et al. CANCER
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
- (2012) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma
- (2012) Philippe Moreau et al. CLINICAL PHARMACOKINETICS
- Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
- (2012) Margreke J.E. Brill et al. CLINICAL PHARMACOKINETICS
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
- (2011) R. W. .F. van Leeuwen et al. ANNALS OF ONCOLOGY
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
- (2011) Ticiana B. Leal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkinʼs Lymphoma
- (2011) Andrzej Hellmann et al. CLINICAL PHARMACOKINETICS
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis
- (2010) W. Lamm et al. ANNALS OF HEMATOLOGY
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
- (2010) Donna E. Reece et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study
- (2010) Karthik Venkatakrishnan et al. CLINICAL THERAPEUTICS
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
- (2010) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
- (2009) D. E. Reece et al. BLOOD
- Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma
- (2009) David I. Quinn et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics and drug metabolism in the elderly
- (2009) Ulrich Klotz DRUG METABOLISM REVIEWS
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
- (2009) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
- (2008) P. Moreau et al. HAEMATOLOGICA
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
- (2008) A. D. Wechalekar et al. HAEMATOLOGICA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More